A citation-based method for searching scientific literature

Richard Furie, Michelle Petri, Omid Zamani, Ricard Cervera, Daniel J Wallace, Dana Tegzová, Jorge Sanchez-Guerrero, Andreas Schwarting, Joan T Merrill, W Winn Chatham, William Stohl, Ellen M Ginzler, Douglas R Hough, Z John Zhong, William Freimuth, Ronald F van Vollenhoven. Arthritis Rheum 2011
Times Cited: 720







List of co-cited articles
756 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Sandra V Navarra, Renato M Guzmán, Alberto E Gallacher, Stephen Hall, Roger A Levy, Renato E Jimenez, Edmund K-M Li, Mathew Thomas, Ho-Youn Kim, Manuel G León,[...]. Lancet 2011
917
81

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
William Stohl, Andreas Schwarting, Masato Okada, Morton Scheinberg, Andrea Doria, Anne E Hammer, Christi Kleoudis, James Groark, Damon Bass, Norma Lynn Fox,[...]. Arthritis Rheumatol 2017
111
30

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Brad H Rovin, Richard Furie, Kevin Latinis, R John Looney, Fernando C Fervenza, Jorge Sanchez-Guerrero, Romeo Maciuca, David Zhang, Jay P Garg, Paul Brunetta,[...]. Arthritis Rheum 2012
628
23

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Joan T Merrill, C Michael Neuwelt, Daniel J Wallace, Joseph C Shanahan, Kevin M Latinis, James C Oates, Tammy O Utset, Caroline Gordon, David A Isenberg, Hsin-Ju Hsieh,[...]. Arthritis Rheum 2010
650
22

A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Fengchun Zhang, Sang-Cheol Bae, Damon Bass, Myron Chu, Sally Egginton, David Gordon, David A Roth, Jie Zheng, Yoshiya Tanaka. Ann Rheum Dis 2018
55
38

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Antonis Fanouriakis, Myrto Kostopoulou, Alessia Alunno, Martin Aringer, Ingeborg Bajema, John N Boletis, Ricard Cervera, Andrea Doria, Caroline Gordon, Marcello Govoni,[...]. Ann Rheum Dis 2019
308
21

Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Eric F Morand, Richard Furie, Yoshiya Tanaka, Ian N Bruce, Anca D Askanase, Christophe Richez, Sang-Cheol Bae, Philip Z Brohawn, Lilia Pineda, Anna Berglind,[...]. N Engl J Med 2020
156
21



Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
Richard Furie, Munther Khamashta, Joan T Merrill, Victoria P Werth, Kenneth Kalunian, Philip Brohawn, Gabor G Illei, Jorn Drappa, Liangwei Wang, Stephen Yoo. Arthritis Rheumatol 2017
336
18


Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Daniel J Wallace, Richard A Furie, Yoshiya Tanaka, Kenneth C Kalunian, Marta Mosca, Michelle A Petri, Thomas Dörner, Mario H Cardiel, Ian N Bruce, Elisa Gomez,[...]. Lancet 2018
151
17

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
M A Dooley, F Houssiau, C Aranow, D P D'Cruz, A Askanase, D A Roth, Z J Zhong, S Cooper, W W Freimuth, E M Ginzler. Lupus 2013
142
15

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
Ronald F van Vollenhoven, Michelle A Petri, Ricard Cervera, David A Roth, Beulah N Ji, Christi S Kleoudis, Z John Zhong, William Freimuth. Ann Rheum Dis 2012
214
14

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Daniel J Wallace, William Stohl, Richard A Furie, Jeffrey R Lisse, James D McKay, Joan T Merrill, Michelle A Petri, Ellen M Ginzler, W Winn Chatham, W Joseph McCune,[...]. Arthritis Rheum 2009
324
14

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Munther Khamashta, Joan T Merrill, Victoria P Werth, Richard Furie, Kenneth Kalunian, Gabor G Illei, Jorn Drappa, Liangwei Wang, Warren Greth. Ann Rheum Dis 2016
246
14

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Michelle Petri, William Stohl, Winn Chatham, W Joseph McCune, Marc Chevrier, Jeff Ryel, Virginia Recta, John Zhong, William Freimuth. Arthritis Rheum 2008
244
14

Combined oral contraceptives in women with systemic lupus erythematosus.
Michelle Petri, Mimi Y Kim, Kenneth C Kalunian, Jennifer Grossman, Bevra H Hahn, Lisa R Sammaritano, Michael Lockshin, Joan T Merrill, H Michael Belmont, Anca D Askanase,[...]. N Engl J Med 2005
573
13



Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
William Stohl, Falk Hiepe, Kevin M Latinis, Mathew Thomas, Morton A Scheinberg, Ann Clarke, Cynthia Aranow, Frank R Wellborne, Carlos Abud-Mendoza, Douglas R Hough,[...]. Arthritis Rheum 2012
198
11



Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.
Kevin P Baker, Bryan M Edwards, Sarah H Main, Gil H Choi, Ruth E Wager, Wendy G Halpern, Patrick B Lappin, Todd Riccobene, Donara Abramian, Les Sekut,[...]. Arthritis Rheum 2003
287
10

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.
J Zhang, V Roschke, K P Baker, Z Wang, G S Alarcón, B J Fessler, H Bastian, R P Kimberly, T Zhou. J Immunol 2001
505
10

Novel evidence-based systemic lupus erythematosus responder index.
Richard A Furie, Michelle A Petri, Daniel J Wallace, Ellen M Ginzler, Joan T Merrill, William Stohl, W Winn Chatham, Vibeke Strand, Arthur Weinstein, Marc R Chevrier,[...]. Arthritis Rheum 2009
250
10

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
Kenneth C Kalunian, Joan T Merrill, Romeo Maciuca, Jacqueline M McBride, Michael J Townsend, Xiaohui Wei, John C Davis, William P Kennedy. Ann Rheum Dis 2016
191
10

Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
Luca Iaccarino, Silvano Bettio, Rossella Reggia, Margherita Zen, Micol Frassi, Laura Andreoli, Mariele Gatto, Silvia Piantoni, Linda Nalotto, Franco Franceschini,[...]. Arthritis Care Res (Hoboken) 2017
62
16

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Y K Onno Teng, Ian N Bruce, Betty Diamond, Richard A Furie, Ronald F van Vollenhoven, David Gordon, James Groark, Robert B Henderson, Mary Oldham, Paul P Tak. BMJ Open 2019
31
29

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.
F Mackay, S A Woodcock, P Lawton, C Ambrose, M Baetscher, P Schneider, J Tschopp, J L Browning. J Exp Med 1999
9

First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study.
Andreas Schwarting, Johann O Schroeder, Tobias Alexander, Marc Schmalzing, Christoph Fiehn, Christof Specker, Alessandra Perna, Constanze Cholmakow-Bodechtel, Volker B Koscielny, Heike Carnarius. Rheumatol Ther 2016
29
31

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.
D Gladman, E Ginzler, C Goldsmith, P Fortin, M Liang, M Urowitz, P Bacon, S Bombardieri, J Hanly, E Hay,[...]. Arthritis Rheum 1996
9

New therapies for systemic lupus erythematosus - past imperfect, future tense.
Grainne Murphy, David A Isenberg. Nat Rev Rheumatol 2019
45
20

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Richard Furie, Brad H Rovin, Frédéric Houssiau, Ana Malvar, Y K Onno Teng, Gabriel Contreras, Zahir Amoura, Xueqing Yu, Chi-Chiu Mok, Mittermayer B Santiago,[...]. N Engl J Med 2020
40
22

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
Susan Manzi, Jorge Sánchez-Guerrero, Joan T Merrill, Richard Furie, Dafna Gladman, Sandra V Navarra, Ellen M Ginzler, David P D'Cruz, Andrea Doria, Simon Cooper,[...]. Ann Rheum Dis 2012
220
8

The BAFF/APRIL system in SLE pathogenesis.
Fabien B Vincent, Eric F Morand, Pascal Schneider, Fabienne Mackay. Nat Rev Rheumatol 2014
203
8


Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
Ronald F van Vollenhoven, Marta Mosca, George Bertsias, David Isenberg, Annegret Kuhn, Kirsten Lerstrøm, Martin Aringer, Hendrika Bootsma, Dimitrios Boumpas, Ian N Bruce,[...]. Ann Rheum Dis 2014
282
8

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
William Stohl, Samy Metyas, Soon-Min Tan, Gurtej S Cheema, Bonifacia Oamar, Dong Xu, Viktor Roschke, Youmei Wu, Kevin P Baker, David M Hilbert. Arthritis Rheum 2003
320
8


Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
Ronald F van Vollenhoven, Bevra H Hahn, George C Tsokos, Carrie L Wagner, Peter Lipsky, Zahi Touma, Victoria P Werth, Robert M Gordon, Bei Zhou, Benjamin Hsu,[...]. Lancet 2018
115
8

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
Tobias Alexander, Ramona Sarfert, Jens Klotsche, Anja A Kühl, Andrea Rubbert-Roth, Hannes-Martin Lorenz, Jürgen Rech, Bimba F Hoyer, Qingyu Cheng, Aderajew Waka,[...]. Ann Rheum Dis 2015
169
8

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Brad H Rovin, Neil Solomons, William F Pendergraft, Mary Anne Dooley, James Tumlin, Juanita Romero-Diaz, Lidia Lysenko, Sandra V Navarra, Robert B Huizinga. Kidney Int 2019
59
13

Systemic lupus erythematosus disease activity index 2000.
Dafna D Gladman, Dominique Ibañez, Murray B Urowitz. J Rheumatol 2002
8

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Jonathan C W Edwards, Leszek Szczepanski, Jacek Szechinski, Anna Filipowicz-Sosnowska, Paul Emery, David R Close, Randall M Stevens, Tim Shaw. N Engl J Med 2004
7

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
Ian N Bruce, Aidan G O'Keeffe, Vern Farewell, John G Hanly, Susan Manzi, Li Su, Dafna D Gladman, Sang-Cheol Bae, Jorge Sanchez-Guerrero, Juanita Romero-Diaz,[...]. Ann Rheum Dis 2015
193
7

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ellen M Ginzler, Daniel J Wallace, Joan T Merrill, Richard A Furie, William Stohl, W Winn Chatham, Arthur Weinstein, James D McKay, W Joseph McCune, Z John Zhong,[...]. J Rheumatol 2014
94
7

Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
Richard A Furie, Daniel J Wallace, Cynthia Aranow, James Fettiplace, Barbara Wilson, Prafull Mistry, David A Roth, David Gordon. Arthritis Rheumatol 2018
26
26

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
Ioannis Parodis, Christopher Sjöwall, Andreas Jönsen, Daniel Ramsköld, Agneta Zickert, Martina Frodlund, Azita Sohrabian, Laurent Arnaud, Johan Rönnelid, Vivianne Malmström,[...]. Autoimmun Rev 2017
40
17

Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study.
Luca Iaccarino, Laura Andreoli, Elena Bartoloni Bocci, Alessandra Bortoluzzi, Fulvia Ceccarelli, Fabrizio Conti, Rossella De Angelis, Ginevra De Marchi, Salvatore De Vita, Andrea Di Matteo,[...]. J Autoimmun 2018
35
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.